Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus FORADIL CERTIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus FORADIL CERTIHALER.
FORADIL vs FORADIL CERTIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
One inhalation (12 mcg) twice daily via oral inhalation.
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Category C
Category C
Bronchodilator
Bronchodilator